EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSPTXG00000006929
Gene Symbol: GRIK2
3 Cross references
334 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSPTXG00000004190
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSPTXG00000012172
Gene Symbol: GRIK4
1 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSPTXG00000019124
Gene Symbol: GRIK5
3 Cross references
303 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSPTXG00000008104
Gene Symbol: GRM2
1 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSPTXG00000016625
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSPTXG00000001252
Gene Symbol: GRM5
3 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutaminase

Ensembl ID : ENSPTXG00000008306
Gene Symbol: GLS
3 Cross references
303 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glycogen Synthase Kinase 3 Alpha

Ensembl ID : ENSPTXG00000019133
Gene Symbol: GSK3A
3 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glycogen Synthase Kinase 3 Beta

Ensembl ID : ENSPTXG00000014811
Gene Symbol: GSK3B
3 Cross references
238 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSPTXG00000009814
Gene Symbol: GHRHR
1 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSPTXG00000013337
Gene Symbol: GHSR
1 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).